Loading...
TTOO logo

T2 Biosystems, Inc.OTCPK:TTOO 株式レポート

時価総額 US$19.6k
株価
US$0.0008
私の公正価値
n/a
1Y-97.9%
7D0%
ポートフォリオ価値
​
表示

T2 Biosystems, Inc.

OTCPK:TTOO 株式レポート

時価総額：US$19.6k

T2 Biosystems（TTOO）株式概要

体外診断薬会社であるT2バイオシステムズ社は、診断薬および製品候補の開発・販売を米国内外で行っている。 詳細

TTOO ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長0/6
過去の実績0/6
財務の健全性0/6
配当金0/6

リスク分析

意味のある時価総額がありません ( $20K )

最新の財務報告は1年以上前のものである

US市場と比較して、過去 3 か月間の株価の変動が非常に大きい


TTOO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

T2 Biosystems, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要T2 Biosystems
過去の株価
現在の株価US$0.003
52週高値US$0.17
52週安値US$0.0001
ベータ0
1ヶ月の変化1,400.00%
3ヶ月変化100.00%
1年変化-97.93%
3年間の変化-99.90%
5年間の変化-99.90%
IPOからの変化-99.90%

最新ニュース

Recent updates

分析記事 • Apr 18

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

T2 Biosystems, Inc.'s ( NASDAQ:TTOO ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy...
Seeking Alpha • Oct 13

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems (NASDAQ:TTOO) said on Thursday it had planned to to complete development of, and commercialize, a diagnostic test to detect early Lyme disease. The company expects to begin marketing and sales in the United States as a Laboratory Developed Test (LDT) in 2023. "We believe the T2Lyme Panel will potentially allow clinicians to ensure patients receive appropriate therapy faster, and prevent the negative impact of a delay in delivery of appropriate therapy and the overuse of antibiotics,” said John Sperzel, CEO of T2Biosystems. The molecular diagnostic test, T2Lyme panel, is designed to run on the FDA-cleared T2Dx Instrument and to detect Borrelia burgdorferi, the bacteria that causes Lyme disease. Lyme disease is a bacterial infection caused by the genes Borrelia and is transmitted to humans through the bite of infected ticks. About 476,000 Americans may get Lyme disease each year in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
Seeking Alpha • Sep 29

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

Biomedical Advanced Research and Development Authority (or BARDA) is providing T2 Biosystems (NASDAQ:TTOO) an additional $3.7M in funding for the multiple-year cost-share contract. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The total potential BARDA funding if all contract options are exercised is $62M, reflecting a reduction in the scope of work under contract option 3. "We are pleased to advance the U.S. clinical trials for the T2Resistance Panel and T2Biothreat Panel, in collaboration with BARDA, and subsequently file submissions with FDA for U.S. regulatory clearance. These new products will expand the test menu on our T2Dx Instrument and have the potential to reduce the threat of antimicrobial resistance and protect the nation from biothreat pathogens.” stated John Sperzel, Chairman and CEO.
Seeking Alpha • Sep 22

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems (NASDAQ:TTOO) on Thursday said it had entered into a distribution agreement in the Baltic region for the sale of its products. Shares of the micro-cap diagnostics company jumped 17.3% to $0.10 after hours. It is worth noting that TTOO stock had earlier closed 11.8% lower to notch its eight straight session in the red. As per the agreement with the distributor, TTOO can sell products such as its T2Bacteria Panel, which can identify sepsis-causing bacteria, and its T2Candida Panel, which can detect fungal pathogens. "We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Lithuania, Latvia, and Estonia,” TTOO CEO John Sperzel said in a statement.
Seeking Alpha • Aug 26

T2 Biosystems' Survival Riddle

Summary T2's ongoing survival is a marvel to behold. T2's products fill key niches but have yet to show any viable commercial appeal. The elephant in the room for T2 shareholders is whether it will ever participate in any upside that may reside in its intellectual property. T2 Biosystems (TTOO) is a bygone favorite of mine that has bumped along on the fringes. I last discussed it in 08/2020's "COVID-19 Opportunity Knocks, T2 Answers". At the time, T2 was hoping to use interest in its rapid COVID diagnostics to place its T2Dx diagnostic device in hospitals. T2's strategy has been successful, but at an insufficient scale to turn it around. Placing devices is an important focus of T2's business development strategy. During T2's Q2 2022 earnings call (the "Call"), CEO Sperzel advised that its strategy was playing out as planned. It was gradually transitioning instruments that had been used for processing T2SARS-CoV-2 panels to use for sepsis testing. As a result, T2 has been experiencing an expected decline in COVID testing. [It] view[s] this development as a positive because it allows [it] to convert COVID-driven instruments to sepsis testing. As a reminder, [it] sold 47 T2Dx instruments to hospital microbiology labs during 2020, initially for COVID-19 testing, with the expectation that approximately 80% would convert to ... sepsis test panels over time. Selling instruments is an important driver of revenues for T2. Once an instrument is placed, it generates ongoing revenues. During the Call Sperzel explained: From an instrument pull-through perspective, in the United States, we achieved annualized sepsis tests utilization of $106,000 for legacy instruments. We continue to believe that annualized US sepsis test utilization will reach $200,000 per instrument and we have a number of customers that have already surpassed that target. We believe there is a significant market opportunity for our products, and we're excited to expand our presence in new and existing customers. During the Call, he also advised that T2's installed base of instruments includes a total of 155, 94 in the US and 61 internationally. When you consider that the instrument was FDA approved in 09/2014, this is a discouraging total. T2 has gone from troubled to extremely troubled, but somehow it keeps on ticking. My first (11/2019) T2 article, "T2: Navigating The Danger Zone", presented a cautiously optimistic view of this company. T2 had snagged its FDA approval back in 2014 for its instrument, but was, and still is, wallowing in the danger zone as it works to commercialize its T2Dx diagnostic device. It's hard to believe that T2, which currently (08/25/2022) trades for ~$0.13 went public in 08/2014 at ~$11.00 and subsequently traded >$20.00. Cheap does not a bargain make. T2's current down and nearly out share price reflects some very real problems that are dogging this company. Its rapid diagnostic products are quite attractive from any patient's point of view. The problem is that T2 has yet to figure out how to market them in commercially sufficient quantities to meet its expenses, much less earn a profit. T2's long-fought efforts for commercial viability have decimated the company's shares. It is struggling to maintain its NASDAQ listing. It currently anticipates a reverse stock split of somewhere between 1-for-10 and 1-for-50. If it would elect the 1 for 50 ratio, a shareholder who currently owns 50 shares trading at $0.13 would instead own 1 share worth $6.50; if it elects the 1 for 10 ratio, then shareholder would own 5 shares worth $1.30, still aggregating $6.50. T2 has an outstanding debt financing, originally for $40 million, with CRG. This financing has long been a concern of mine as I discuss at length in "T2: A Catch With A Catch". This concern is only exacerbated by T2's ongoing losses. The CRG loan is secured by a lien on substantially all of T2's assets, including its intellectual property. The loan requires T2 to maintain a minimum cash balance of $5 million along with other covenants. It is prepayable. In its latest 10-K, T2 advises: ...[It] intend[s] to continue to evaluate options to refinance the Term Loan Agreement, which becomes due on December 30, 2023. There can be no assurances that we will be able to refinance on terms favorable or at all. The amounts involved in any such transactions, individually or in the aggregate, may be material. Because the loan and its covenants are so important, T2 advised during the Call that it was then in compliance with all its loan covenants. As I recall from past review, this is a common bit of assurance that T2 has so far been able to provide during its quarterly earnings calls. T2 has a bevy of highly attractive products which have not proven financially viable. The issue with T2 that is especially frustrating relates to the extreme appeal of its products from a patient's point of view. Its current products are shown on its Q2 2022 presentation slide below: seekingalpha.com T2's rapid results are a godsend for patients who need to get a health screening, but who can ill afford long delays that are prevalent in the industry.

株主還元

TTOOUS BiotechsUS 市場
7D0%1.2%2.1%
1Y-97.9%41.9%30.6%

業界別リターン: TTOO過去 1 年間で41.9 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: TTOOは、過去 1 年間で30.6 % のリターンを上げたUS市場を下回りました。

価格変動

Is TTOO's price volatile compared to industry and market?
TTOO volatility
TTOO Average Weekly Movement614.9%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

安定した株価: TTOOの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: TTOOの 週次ボラティリティ は過去 1 年間で664%から615%に減少しましたが、依然としてUS株の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
2006n/aCraig Jalbertinvestors.t2biosystems.com

体外診断薬企業であるT2バイオシステムズ社は、診断薬および製品候補の開発・販売を米国内外で行っている。同社の技術は、全血、血漿、血清、唾液、喀痰、脳脊髄液、尿など、精製されていないさまざまなタイプの患者検体から病原体、バイオマーカー、その他の異常を検出することを可能にする。同社はまた、患者検体から様々な診断検査を行う卓上型装置であるT2Dx Instrumentや、敗血症やカンジダ血症の原因となる一般的な血流感染症の致死型を検出する血液から直接採取する分子診断検査パネルであるT2Candidaパネルも提供している；T2Bacteriaパネル：血流感染症の細菌性病原体を検出する血液から直接採取する分子診断検査パネル、T2Resistanceパネル：カルバペネム耐性遺伝子を同定する血液から直接採取する検査パネル、T2Biothreatパネル：T2Dx Instrument上で動作し、生物脅威病原体を検出する血液から直接採取する分子診断検査パネル。さらに、T2Dx Instrument上で動作し、カンジダ・オーリスを検出する血液からの直接分子診断検査であるT2Caurisパネル、T2Dx Instrument上で動作し、ライム病の原因菌を特定する血液からの直接分子診断検査であるT2Lymeパネルを開発している。T2バイオシステムズ社は2006年に設立され、マサチューセッツ州レキシントンに本社を置いています。

T2 Biosystems, Inc. 基礎のまとめ

T2 Biosystems の収益と売上を時価総額と比較するとどうか。
TTOO 基礎統計学
時価総額US$19.63k
収益（TTM）-US$42.95m
売上高(TTM)US$7.68m
0.0x
P/Sレシオ
0.0x
PER（株価収益率

TTOO は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
TTOO 損益計算書（TTM）
収益US$7.68m
売上原価US$26.70m
売上総利益-US$19.03m
その他の費用US$23.93m
収益-US$42.95m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）0
グロス・マージン0.00%
純利益率0.00%
有利子負債／自己資本比率0.0%

TTOO の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/07 08:33
終値2026/05/07 00:00
収益2024/09/30
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

T2 Biosystems, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Benjamin HaynorAlliance Global Partners
Paul KnightBrean Capital Historical (Janney Montgomery)
Karen KoskiBTIG